Media coverage about Incyte Corporation (NASDAQ:INCY) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Incyte Corporation earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.5747345711958 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Investor’s Roundup (Beta Factor Analysis) – Incyte Corporation, (NASDAQ: INCY) – Stock Watch (stocksnewstimes.com)
- Incyte Corporation (NASDAQ: INCY) – Eye-Catching Hot Stocks – Alpha Beta Stock (alphabetastock.com)
- $411.23 Million in Sales Expected for Incyte Corporation (INCY) This Quarter (americanbankingnews.com)
- Lightning Round: Jim Cramer Gives His Opinion On Incyte, Apache And More – Benzinga (benzinga.com)
- Cramer’s lightning round: Don’t give up on Incyte – CNBC.com – CNBC (cnbc.com)
Shares of Incyte Corporation (NASDAQ INCY) traded up $2.45 during mid-day trading on Tuesday, reaching $107.21. 2,021,900 shares of the company’s stock were exchanged, compared to its average volume of 1,944,065. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01. Incyte Corporation has a 12-month low of $98.49 and a 12-month high of $153.15.
Several equities research analysts have weighed in on INCY shares. Raymond James Financial, Inc. upgraded shares of Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 target price on the stock in a report on Monday, September 11th. J P Morgan Chase & Co reiterated a “buy” rating and issued a $149.00 target price on shares of Incyte Corporation in a report on Thursday, August 31st. Oppenheimer Holdings, Inc. reiterated a “hold” rating and issued a $135.00 target price on shares of Incyte Corporation in a report on Thursday, August 31st. BMO Capital Markets reissued an “outperform” rating and set a $172.00 price objective on shares of Incyte Corporation in a research report on Monday, August 28th. Finally, Argus reissued a “buy” rating and set a $150.00 price objective on shares of Incyte Corporation in a research report on Wednesday, September 13th. Seven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $144.98.
COPYRIGHT VIOLATION WARNING: “Incyte Corporation (INCY) Receiving Somewhat Positive Press Coverage, Study Finds” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2017/11/14/incyte-corporation-incy-receiving-somewhat-positive-press-coverage-study-finds.html.
In other news, EVP Barry P. Flannelly sold 714 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $124.25, for a total transaction of $88,714.50. Following the completion of the sale, the executive vice president now owns 15,496 shares in the company, valued at approximately $1,925,378. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Paula J. Swain sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $140.00, for a total transaction of $2,800,000.00. Following the sale, the executive vice president now owns 55,067 shares of the company’s stock, valued at approximately $7,709,380. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,062 shares of company stock valued at $12,652,893. Corporate insiders own 17.70% of the company’s stock.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.